The Road to a Cure: Where MS Research Stands in 2026
By Locke’s Promise
For the nearly one million Americans living with Multiple Sclerosis (MS), one question continues to drive hope, advocacy, and research: How close are we to a cure?
The encouraging news is that we have never been closer.
While there is still no cure for MS, researchers, clinicians, advocacy organizations, and people living with the disease have helped transform the MS landscape over the last decade. Today's research is no longer focused solely on slowing disease activity—it is increasingly aimed at repairing damage, restoring lost function, preventing MS altogether, and ultimately ending the disease.
At Locke’s Promise, we believe that knowledge creates hope. Here's a look at where MS research stands today and why the future has never looked brighter.
A New Global Strategy:
Pathways to Cures
The National Multiple Sclerosis Society's research framework, known as Pathways to Cures, represents one of the most ambitious collaborative efforts in MS history. Supported by more than 30 MS organizations worldwide, this roadmap focuses on three major goals:
Stop MS – Prevent disease progression and new damage.
Restore Function – Repair nervous system damage and recover lost abilities.
End MS Through Prevention – Identify causes and stop MS before it starts.
This shift is significant. For many years, success was measured by reducing relapses. Today, researchers are asking much bigger questions:
Can damaged myelin be rebuilt?
Can disability be reversed?
Can we identify people at risk before symptoms begin?
Can MS eventually become preventable?
Those questions are now driving the majority of new research investments.
Research Funding Remains Strong
In April 2025, the National MS Society announced $18.1 million in new multi-year research funding, supporting 16 major research grants and 28 fellowships and early-career awards. The organization continues to invest more than $30 million annually in over 200 research projects worldwide.
Importantly, the Society has now invested more than $1 billion in MS research since its founding, helping advance virtually every approved MS treatment available today.
However, challenges remain. In 2025, advocates raised concerns regarding the loss of federal funding for the Department of Defense's Multiple Sclerosis Research Program, highlighting the need for continued public and private investment in scientific discovery.
The Biggest Breakthrough Area: Repairing Myelin
Perhaps the most exciting frontier in MS research is remyelination.
MS damages myelin, the protective coating surrounding nerve fibers. While existing disease-modifying therapies help reduce inflammation and new attacks, they generally cannot repair damage that has already occurred.
That may be changing.
Researchers across the world are investigating therapies designed to stimulate the body's own repair mechanisms, encouraging new myelin growth around damaged nerves. Recent scientific reviews report growing evidence from clinical trials that remyelination is achievable in people living with MS.
Several experimental therapies are now making headlines:
PIPE-307, currently in Phase II testing, aims to stimulate cells that produce myelin.
Researchers are exploring compounds that encourage oligodendrocyte cells to rebuild damaged myelin.
Multiple Phase II studies are evaluating therapies specifically designed to restore nervous system function rather than simply reduce relapses.
For people who have experienced mobility loss, vision changes, balance issues, fatigue, or cognitive decline, the possibility of rebuilding damaged pathways represents a monumental shift in thinking.
Earlier Diagnosis Means Better Outcomes
Another major advancement involves diagnosing MS earlier than ever before.
Updated diagnostic criteria now incorporate advanced biomarkers, MRI findings, and laboratory indicators that can help identify MS sooner and more accurately. Earlier diagnosis means earlier treatment, which can significantly reduce long-term disability.
Researchers are also pursuing ways to recognize individuals who may be at heightened risk before symptoms emerge. Studies examining viral exposure patterns, genetics, immune signatures, and blood biomarkers could eventually make prevention possible.
The Epstein-Barr Virus Connection
One of the most compelling discoveries of recent years is the growing evidence linking Epstein-Barr Virus (EBV) to MS.
Researchers increasingly believe EBV infection may be a critical trigger in the development of MS. Multiple research teams are working to better understand this relationship and explore prevention strategies, including vaccines and targeted interventions.
If scientists ultimately learn how to interrupt this pathway, it could become one of the most important breakthroughs in preventing future MS cases.
New Hope for Progressive MS
Historically, progressive forms of MS have been the most difficult to treat.
Today, that reality is beginning to change.
The International Progressive MS Alliance—supported and co-founded by the National MS Society—continues funding global efforts focused specifically on progressive disease. Researchers are investigating:
Neuroprotection
Brain metabolism
Remyelination
Biomarkers of progression
Precision medicine approaches tailored to individual patients
The goal is not merely slowing progression but eventually halting it altogether.
Emerging Technologies: CAR-T Cells and Precision Medicine
Researchers are now applying innovations first developed for cancer treatment to MS.
One example is CAR-T cell therapy, which retrains a patient's immune cells to target harmful immune responses. Early studies suggest this approach could potentially "reset" immune activity responsible for attacking myelin.
At the same time, precision medicine efforts aim to identify biological signatures unique to each person with MS. Future treatments may be customized based on genetics, biomarkers, immune profiles, and disease subtype rather than relying on a one-size-fits-all approach.
So, Where Do We Stand?
If we're being honest, we are not at a cure—yet.
But we are dramatically closer than we were even ten years ago.
Today we have:
✅ More than 20 approved disease-modifying therapies
✅ Better diagnostic tools
✅ Growing understanding of risk factors like EBV
✅ Active remyelination research
✅ Global collaboration around cure-focused science
✅ Significant annual research investments dedicated to stopping, restoring, and preventing MS
For the first time, the conversation is no longer limited to managing MS. Researchers are actively pursuing ways to repair damage, restore function, prevent future cases, and potentially eliminate the disease altogether.
From All of Us at Locke’s Promise
At Locke’s Promise, we know every research breakthrough represents more than a scientific achievement. It represents a mother who wants to keep walking with her children. A husband who wants to keep working. A young adult determined to pursue a dream despite a diagnosis.
The road ahead is still long, but progress is accelerating.
The message from the research community is clear:
Hope is no longer just a feeling. It's being built one discovery at a time.
Together, we will keep advocating, educating, fundraising, and supporting the research that moves us closer to a world free of MS.
Because a cure isn't just possible—it is worth fighting for.
Sources: National Multiple Sclerosis Society, International Progressive MS Alliance, National Institutes of Health-supported research, and peer-reviewed MS research publications. [nationalms...ociety.org], [nationalms...ociety.org], [nationalms...ociety.org], [pubmed.ncb...lm.nih.gov]